Navigation Links
Dr. Reddy's To Launch 'Polypill' For Treating Heart Disease

Indian pharma major Dr. Reddy's Laboratories will launch a first-of-its-kind pill to tackle heart diseases in the second half of 2007, it was announced Thursday. //

The company has teamed up with researchers at University of Auckland, New Zealand, for trials of the groundbreaking 'polypill' that combines four medicines including aspirin and statin, commonly used to treat heart ailments.

India records nearly 2.8 million deaths a year due to cardio-vascular diseases.

'Trials in India are underway. We are conducting trials on 220 patients and after testing on 440 more cases, the product will be launched in the Indian market,' said Satish Reddy, managing director of Dr. Reddy's Lab.

'We have already received the necessary approval from the government for conducting the trails. We hope the product will be available to masses in the second quarter of 2007,' he told reporters at the New Zealand High Commission here.

'This is first-of-its-kind drug in the world to tackle heart problem and will open newer vistas to handle such ailments,' Reddy told IANS, adding it will cost Rs.100 for 30 tablets.

New Zealand's High Commissioner to India Graeme Waters said: 'This project holds open the possibility of revolutionising an important aspect of healthcare in both developing and developed countries.'

The new drug will be cheaper to administer and more effective in preventing strokes and heart attacks, said Anthony Rodgers, a researcher at Auckland University.

The trial aims to confirm that the polypill is effective in lowering cholesterol and blood pressure - known causes of heart attacks and strokes.

The Health Research Council of New Zealand invested NZ$350,000 to support the overall co-ordination of the trial and recruitment in New Zealand. Dr. Reddy's will invest NZ$ 7.5 million in developing the polypill and providing supplies for clinical trials globally.

Source- IANS
'"/>




Related medicine news :

1. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
2. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
3. Dr. Reddys To Invest $100 Mn In Andhra
4. Dr Reddys Eyeing for Generics Arm of Merck
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. Nutrient Profiling System Launched By Food Officials in UK
7. New Oat And Soy-Based Fat Replacer Launched
8. Launch Of India’s First Virology Course At Pun
9. Race Based Genome Project Launched By Mexico
10. Bird flu In Indonesia: Government To Launch ‘Village Preparedness’ Schee
11. Action Plan Against Drug Deaths Launched
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... The ... candidates for the Board of Commissioners. Individuals interested in volunteer board service are ... diversity of clinical practice settings and across allied health to contribute to its ...
(Date:2/11/2016)... SURPRISE, ARIZ. (PRWEB) , ... February 11, 2016 , ... ... kids,” a group of men, 60 and older, who gather once a year to ... , Besides a love for the game, the more than 50 players who competed ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. ... Infusion Therapy Standards of Practice, to include vascular visualization as a standard practice. ... 85% share of the market, facilitates adherence to this standard with its easy ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services ... a new fundraiser in support of a local boy named Barrett, who has been ... bring awareness to, and rally support for, all local families dealing with childhood cancer. ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce the ... Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge practice ... their homes, offices or at the practices’ local office. It is also one of ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 11, 2016 ... of the "Molecular Diagnostics Reports Bundle" ... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced the addition ... report to their offering. --> ... has announced the addition of the ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
(Date:2/10/2016)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... quarter and full year ended December 31, 2015. ... a transformational year for Vanda with the continued growth ... approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, ... to our U.S. product portfolio builds on this success ...
Breaking Medicine Technology: